AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8694299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (600 micrograms via metered-dose inhaler, 3 puffs 10 min before induction)
Number of subjects: 45
Study 8694299 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 puffs of aerosol containing no medication)
Number of subjects: 45
Study 29555457 — intervention group
Group type: EXPERIMENTAL
Intervention: NP education plus tablet application (interactive conditional logic program)
Number of subjects: 126
Study 29555457 — intervention group
Group type: COMPARATOR
Intervention: NP education alone
Number of subjects: 126
Study 28623713 — intervention group
Group type: EXPERIMENTAL
Intervention: SVE1 (isometric exercise with sinusoidal vibrations; frequency=20Hz, displacement=3.55±0.54mm)
Number of subjects: 19
Study 28623713 — intervention group
Group type: COMPARATOR
Intervention: CON (only isometric exercise)
Number of subjects: 19
Study 26283035 — intervention group
Group type: EXPERIMENTAL
Intervention: Belagenpumatucel-L
Number of subjects: 532
Study 26283035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 532
Study 23677353 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of rhBMP-2
Number of subjects: 40
Study 23677353 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mL of autologous bone
Number of subjects: 40
Study 21149742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received a mailing containing a reminder letter, brochure, digital video disc, and a follow-up telephone call.
Number of subjects: 628
Study 21149742 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group.
Number of subjects: 628
Study 18562777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 2 mg/kg
Number of subjects: 13
Study 18562777 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg
Number of subjects: 13
Study 18562777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15828972 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent distracting mental activity (e.g., free-associating on a task-irrelevant theme or listening to music)
Number of subjects: 0
Study 15828972 — intervention group
Group type: COMPARATOR
Intervention: No concurrent distracting mental activity (control condition)
Number of subjects: 0
Study 12431943 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-coaches track
Number of subjects: 0
Study 12431943 — intervention group
Group type: COMPARATOR
Intervention: Traditional community placement track (shadowing)
Number of subjects: 0
Study 10513967 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual traction with the leg draped free
Number of subjects: 79
Study 10513967 — intervention group
Group type: COMPARATOR
Intervention: Standard fracture table traction
Number of subjects: 79
Study 10513967 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual traction
Number of subjects: 79
Study 7562338 — intervention group
Group type: EXPERIMENTAL
Intervention: Free gingival grafts on the interproximal regenerated tissue
Number of subjects: 28
Study 7562338 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned surgical flaps over the regenerated tissue
Number of subjects: 28
Study 1771935 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg roxatidine nocte
Number of subjects: 20
Study 1771935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6789483 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral Nutrition (PN)
Number of subjects: 42
Study 6789483 — intervention group
Group type: COMPARATOR
Intervention: Standard Nutrition (SN)
Number of subjects: 42
Study 29911496 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training program (resistance, agility, and coordination exercises focusing on plantar flexor muscles) for 12 weeks (3 days per week)
Number of subjects: 26
Study 29911496 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent training program
Number of subjects: 26
Study 27428446 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification method 1
Number of subjects: 376
Study 27428446 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification method 2
Number of subjects: 376
Study 27428446 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification method 3
Number of subjects: 376
Study 25828637 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of etoposide
Number of subjects: 18
Study 24965304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (4 hours time in bed per night for 5 consecutive nights)
Number of subjects: 44
Study 24965304 — intervention group
Group type: EXPERIMENTAL
Intervention: Men during sleep restriction
Number of subjects: 44
Study 24965304 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 44
Study 21214708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2.2 mg kg(‐1) IV
Number of subjects: 42
Study 21214708 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone 1 mg kg(‐1) IV
Number of subjects: 42
Study 21214708 — intervention group
Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 42
Study 21214708 — intervention group
Group type: COMPARATOR
Intervention: Alfaxalone
Number of subjects: 42
Study 19553086 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (3-12 mg/day)
Number of subjects: 78
Study 19553086 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10-20 mg/day)
Number of subjects: 78
Study 19553086 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (300-750 mg/day)
Number of subjects: 78
Study 19553086 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (12-30 mg/day)
Number of subjects: 78
Study 18323223 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Suan Zao Ren Decoction
Number of subjects: 65
Study 18323223 — intervention group
Group type: COMPARATOR
Intervention: Surazepam and Diammonium Glycyrrhizinate (Control)
Number of subjects: 65
Study 15547527 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg daily)
Number of subjects: 24
Study 15547527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11281560 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT)
Number of subjects: 33
Study 9337001 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 173
Study 9337001 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine-sulphadoxine (PSD)
Number of subjects: 173
Study 7953993 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental teeth with plaque index (PI) of 3.0
Number of subjects: 67
Study 7953993 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental teeth with plaque index (PI) of 2.0
Number of subjects: 67
Study 7953993 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (plaque not removed)
Number of subjects: 67
Study 7953993 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental teeth with plaque index (PI) of 1.0 or 0
Number of subjects: 67
Study 3123223 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 80
Study 3123223 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 80
Study 30929507 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 0
Study 30929507 — intervention group
Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 0
Study 28549453 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND)
Number of subjects: 3500
Study 28549453 — intervention group
Group type: COMPARATOR
Intervention: No completion axillary lymph node dissection (ALND)
Number of subjects: 3500
Study 28549453 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion ALND
Number of subjects: 3500
Study 28549453 — intervention group
Group type: COMPARATOR
Intervention: No completion ALND
Number of subjects: 3500
Study 25005818 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood physical disorder
Number of subjects: 398
Study 25005818 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood social environment
Number of subjects: 398
Study 23474245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified antihypertensive therapy
Number of subjects: 4078
Study 21681065 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinomed orthosis
Number of subjects: 0
Study 18728576 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (NC)
Number of subjects: 163
Study 18728576 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 163
Study 16944007 — intervention group
Group type: EXPERIMENTAL
Intervention: YHK
Number of subjects: 8
Study 16944007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12629234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar deep brain stimulation at 90 micros, 130 Hz, adjusting the voltage up to 3 V
Number of subjects: 11
Study 12629234 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar deep brain stimulation
Number of subjects: 11
Study 12629234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar deep brain stimulation at 120 micros, 185 Hz, 4 V
Number of subjects: 11
Study 12629234 — intervention group
Group type: EXPERIMENTAL
Intervention: Longest pulsewidth tested
Number of subjects: 11
Study 12629234 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency changes
Number of subjects: 11
Study 10568896 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies used in the SMILE trial
Number of subjects: 0
Study 9213716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (17 g MgSO4 in 1000 ml isotonic saline)
Number of subjects: 61
Study 9213716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volumes of saline)
Number of subjects: 61
Study 9213716 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 61
Study 9213716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 1909083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100-200 mg daily)
Number of subjects: 57
Study 1909083 — intervention group
Group type: COMPARATOR
Intervention: Mianserin (40-80 mg daily)
Number of subjects: 57
Study 1909083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 57
Study 1909083 — intervention group
Group type: COMPARATOR
Intervention: Mianserin
Number of subjects: 57
Study 1909083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine and Mianserin
Number of subjects: 57
Study 6343041 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (Novo)
Number of subjects: 47
Study 6343041 — intervention group
Group type: COMPARATOR
Intervention: Purified pork insulin
Number of subjects: 47
Study 31574899 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy (AAT) with the presence of a dog during a break (Condition C)
Number of subjects: 20
Study 31574899 — intervention group
Group type: COMPARATOR
Intervention: Normal working process with a break of choice (Condition B)
Number of subjects: 20
Study 31574899 — intervention group
Group type: COMPARATOR
Intervention: Normal working process without a break (Condition A)
Number of subjects: 20
Study 30931588 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (2 probiotic tablets 2× per day for 21 days)
Number of subjects: 34
Study 30931588 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 34
Study 28379172 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) - 4 × 30 s 'flat-out' cycling on an ergometer
Number of subjects: 8
Study 28379172 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 8
Study 28379172 — intervention group
Group type: COMPARATOR
Intervention: REST
Number of subjects: 8
Study 25542064 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg famciclovir
Number of subjects: 167
Study 25542064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (125 mg)
Number of subjects: 167
Study 25542064 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg famciclovir
Number of subjects: 167
Study 25542064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg)
Number of subjects: 167
Study 23592669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative exergame
Number of subjects: 54
Study 23592669 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive exergame
Number of subjects: 54
Study 23592669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative exergame and Competitive exergame
Number of subjects: 54
Study 23592669 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 20489689 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) high-dose
Number of subjects: 38
Study 19502570 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental mobile mandibular advancement splint (MAS) with LDPE connectors
Number of subjects: 30
Study 19502570 — intervention group
Group type: COMPARATOR
Intervention: Conventional mobile MAS (Silensor)
Number of subjects: 30
Study 16680253 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (1 mg x kg(‐1) intramuscular) + remifentanil (0.1 microg x kg(‐1)min(‐1)) + ketamine (0.8 mg x kg(‐1) intravenously)
Number of subjects: 43
Study 16680253 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (0.1 microg x kg(‐1)min(‐1)) + ketamine (0.8 mg x kg(‐1) intravenously)
Number of subjects: 43
Study 15571536 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral resistance training of the operated side (3/wk x 12 weeks)
Number of subjects: 36
Study 15571536 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral neuromuscular electrical stimulation of the operated side (1 h/d x 12 weeks)
Number of subjects: 36
Study 15571536 — intervention group
Group type: COMPARATOR
Intervention: Standard home-based rehabilitation (1 h/d x 12 weeks)
Number of subjects: 36
Study 11523155 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care (tooth brushing after each meal and daily oropharyngeal scrubbing with 1% povidone iodine)
Number of subjects: 0
Study 11523155 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral care (provided by dentists or dental hygienists once a week)
Number of subjects: 0
Study 9020273 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltibant (CP-0127) 0.3, 1.0, or 3.0 microg x kg(‐1) x min(‐1) continuous intravenous infusion
Number of subjects: 504
Study 9020273 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltibant (CP-0127)
Number of subjects: 504
Study 9020273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study 7942581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 2 g/d
Number of subjects: 9
Study 7942581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2833920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 0
Study 2833920 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg)
Number of subjects: 0
Study 2833920 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and lisinopril
Number of subjects: 0
Study 2833920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Lisinopril
Number of subjects: 0
Study 30341961 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (6 mm; GS)
Number of subjects: 101
Study 30341961 — intervention group
Group type: COMPARATOR
Intervention: Long implants (11-15 mm; GG)
Number of subjects: 101
Study 26902851 — intervention group
Group type: EXPERIMENTAL
Intervention: galunisertib + lomustine
Number of subjects: 158
Study 26902851 — intervention group
Group type: EXPERIMENTAL
Intervention: galunisertib
Number of subjects: 158
Study 26902851 — intervention group
Group type: COMPARATOR
Intervention: placebo + lomustine
Number of subjects: 158
Study 26902851 — intervention group
Group type: EXPERIMENTAL
Intervention: all treatment arms
Number of subjects: 158
Study 26902851 — intervention group
Group type: EXPERIMENTAL
Intervention: galunisertib alone
Number of subjects: 158
Study 24013981 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 2930
Study 24013981 — intervention group
Group type: COMPARATOR
Intervention: Comparator treatments (oral antidiabetic drugs, dietary changes, or other insulins)
Number of subjects: 2930
Study 24013981 — intervention group
Group type: COMPARATOR
Intervention: Comparator treatments
Number of subjects: 2930
Study 24288511 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (not specified in detail)
Number of subjects: 30
Study 24288511 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 30
Study 20484612 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 40-mg dose of laropiprant (LRPT)
Number of subjects: 16
Study 20484612 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants (matched for important baseline characteristics)
Number of subjects: 16
Study 18808281 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic Cognitive Interview (H‐CI)
Number of subjects: 0
Study 18808281 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Interview (CI)
Number of subjects: 0
Study 16864469 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid managed care
Number of subjects: 255
Study 16864469 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (other publicly funded adolescents)
Number of subjects: 255
Study 12649628 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 74
Study 12649628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 11732513 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 203
Study 11732513 — intervention group
Group type: COMPARATOR
Intervention: 0.1% bupivacaine with fentanyl
Number of subjects: 203
Study 8820475 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4.5 g omega‐3 fatty acids/day)
Number of subjects: 21
Study 8820475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 1427365 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic injection therapy
Number of subjects: 120
Study 1427365 — intervention group
Group type: COMPARATOR
Intervention: Heater probe therapy
Number of subjects: 120
Study 6994084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at bedtime or twice daily for up to 12 months
Number of subjects: 696
Study 6994084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study 6994084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 696
Study 31313626 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced exercise and RTP (FE+RTP)
Number of subjects: 40
Study 31313626 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary exercise and RTP (VE+RTP)
Number of subjects: 40
Study 31313626 — intervention group
Group type: COMPARATOR
Intervention: Time‐matched stroke‐related education and RTP (Edu+RTP)
Number of subjects: 40
Study 27910260 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS)
Number of subjects: 0
Study 27910260 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving SQ-LNS)
Number of subjects: 0
Study 25827654 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body resistance training (3 times a week for 8 weeks)
Number of subjects: 56
Study 25827654 — intervention group
Group type: COMPARATOR
Intervention: Duration-matched stretch exercises (Control)
Number of subjects: 56
Study 21189483 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine opt-out provider-initiated HIV testing and counseling (PITC)
Number of subjects: 1221
Study 21189483 — intervention group
Group type: COMPARATOR
Intervention: Standard non-PITC (voluntary or diagnostic testing)
Number of subjects: 1221
Study 21189483 — intervention group
Group type: EXPERIMENTAL
Intervention: PITC
Number of subjects: 1221
Study 19589767 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on lifestyle modifications for GERD (10 minutes of education)
Number of subjects: 30
Study 19589767 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 30
Study 17323134 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 136
Study 17323134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 16750703 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 4162
Study 16750703 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 4162
Study 16750703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (including atorvastatin)
Number of subjects: 4162
Study 14658972 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15-45 mg/day)
Number of subjects: 19
Study 14658972 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20-40 mg/day)
Number of subjects: 19
Study 9974197 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 8
Study 9974197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8561100 — intervention group
Group type: EXPERIMENTAL
Intervention: High activity and intensity of response during infancy (measured at 8 months of age)
Number of subjects: 640
Study 8561100 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for females
Number of subjects: 640
Study 2106277 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate hypoosmolar solution (40 mOsmol/L)
Number of subjects: 14
Study 2106277 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate isoosmolar solution (288 mOsmol/L)
Number of subjects: 14
Study 7373088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (1,000 mg/day for five days)
Number of subjects: 97
Study 7373088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 97
Study 7373088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 30795718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fotonovela
Number of subjects: 303
Study 30795718 — intervention group
Group type: COMPARATOR
Intervention: Traditional brochure
Number of subjects: 303